超跌太多了30%，今_老虎社区_美港股上老虎 - 老虎社区

点赞
评论
收藏

超跌太多了30%，今晚至少反弹10%吧

诺和诺德Q2营收略低于预期，Wegovy表现亮眼，股价夜盘涨超2%

诺和诺德第二季度销售额768.6亿丹麦克朗，市场预估769.9亿丹麦克朗。净利润265.0亿丹麦克朗，市场预期270.1亿丹麦克朗。息税前利润334.5亿丹麦克朗，市场预期344.5亿丹麦克朗。诺和诺德表示，目前预计全年自由现金流将达到350亿至450亿丹麦克朗。诺和诺德预计，未来几年资本支出占销售额的比例将维持在低双位数区间。诺和诺德仍预计按固定汇率计算，全年营业利润增长10%至16%。财报发布后，诺和诺德夜盘涨超2%。

诺和诺德Q2营收略低于预期，Wegovy表现亮眼，股价夜盘涨超2%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

点赞

举报

评论

推荐
最新

empty

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":464627998179688,"tweetId":"464627998179688","gmtCreate":1754460052808,"gmtModify":1754460054640,"author":{"id":3540680319507322,"idStr":"3540680319507322","authorId":3540680319507322,"authorIdStr":"3540680319507322","name":"OtisBen","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":18,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>超跌太多了30%，今晚至少反弹10%吧</p></body></html>","htmlText":"<html><head></head><body><p>超跌太多了30%，今晚至少反弹10%吧</p></body></html>","text":"超跌太多了30%，今晚至少反弹10%吧","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/464627998179688","repostId":1146985628,"repostType":2,"repost":{"id":"1146985628","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1754459010,"share":"https://www.laohu8.com/m/news/1146985628?lang=&edition=full","pubTime":"2025-08-06 13:43","market":"us","language":"zh","title":"诺和诺德Q2营收略低于预期，Wegovy表现亮眼，股价夜盘涨超2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146985628","media":"老虎资讯综合","summary":"诺和诺德第二季度销售额768.6亿丹麦克朗，市场预估769.9亿丹麦克朗。净利润265.0亿丹麦克朗，市场预期270.1亿丹麦克朗。息税前利润334.5亿丹麦克朗，市场预期344.5亿丹麦克朗。诺和诺德表示，目前预计全年自由现金流将达到350亿至450亿丹麦克朗。诺和诺德预计，未来几年资本支出占销售额的比例将维持在低双位数区间。诺和诺德仍预计按固定汇率计算，全年营业利润增长10%至16%。财报发布后，诺和诺德夜盘涨超2%。","content":"<html><head></head><body><p>8月6日，<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>公布2025年第二季度财报：</p><ul style=\"\"><li><p><strong>销售额</strong>为768.6亿丹麦克朗，同比增长13%，略低于市场预期的769.9亿丹麦克朗；</p></li><li><p><strong>净利润</strong>为265亿丹麦克朗，同比增长32%，低于预期的270.1亿丹麦克朗；</p></li><li><p>息税前利润（EBIT）为334.5亿丹麦克朗，亦低于预期的344.5亿丹麦克朗。</p></li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c560bcd468d116d176bb173115b82a78\" tg-width=\"732\" tg-height=\"465\"/></p><p>核心产品方面，减重药Wegovy销售额达195.3亿丹麦克朗，<strong>超出</strong>市场预期（192亿）；糖尿病药Ozempic销售额为318亿丹麦克朗，<strong>略低于</strong>预期的322.2亿。</p><p>诺和诺德上半年净销售额为1549.44亿丹麦克朗，同比增长16%；净利润为555.37亿丹麦克朗，同比增长22%；稀释每股收益为12.49美元，同比增长23%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/357ae4b633b62dd71534aeb01e16508a\" title=\"\" tg-width=\"754\" tg-height=\"322\"/></p><p>诺和诺德表示，目前预计全年自由现金流将达到350亿至450亿丹麦克朗。诺和诺德预计，未来几年资本支出占销售额的比例将维持在低双位数区间（即10%-15%左右）。诺和诺德仍预计按固定汇率计算，全年销售额增长8%至14%。</p><p>财报发布后，诺和诺德夜盘涨超2%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bd170476cc3735d1d4c7222fe4539458\" title=\"\" tg-width=\"913\" tg-height=\"443\"/></p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德Q2营收略低于预期，Wegovy表现亮眼，股价夜盘涨超2%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德Q2营收略低于预期，Wegovy表现亮眼，股价夜盘涨超2%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-08-06 13:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>8月6日，<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>公布2025年第二季度财报：</p><ul style=\"\"><li><p><strong>销售额</strong>为768.6亿丹麦克朗，同比增长13%，略低于市场预期的769.9亿丹麦克朗；</p></li><li><p><strong>净利润</strong>为265亿丹麦克朗，同比增长32%，低于预期的270.1亿丹麦克朗；</p></li><li><p>息税前利润（EBIT）为334.5亿丹麦克朗，亦低于预期的344.5亿丹麦克朗。</p></li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c560bcd468d116d176bb173115b82a78\" tg-width=\"732\" tg-height=\"465\"/></p><p>核心产品方面，减重药Wegovy销售额达195.3亿丹麦克朗，<strong>超出</strong>市场预期（192亿）；糖尿病药Ozempic销售额为318亿丹麦克朗，<strong>略低于</strong>预期的322.2亿。</p><p>诺和诺德上半年净销售额为1549.44亿丹麦克朗，同比增长16%；净利润为555.37亿丹麦克朗，同比增长22%；稀释每股收益为12.49美元，同比增长23%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/357ae4b633b62dd71534aeb01e16508a\" title=\"\" tg-width=\"754\" tg-height=\"322\"/></p><p>诺和诺德表示，目前预计全年自由现金流将达到350亿至450亿丹麦克朗。诺和诺德预计，未来几年资本支出占销售额的比例将维持在低双位数区间（即10%-15%左右）。诺和诺德仍预计按固定汇率计算，全年销售额增长8%至14%。</p><p>财报发布后，诺和诺德夜盘涨超2%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bd170476cc3735d1d4c7222fe4539458\" title=\"\" tg-width=\"913\" tg-height=\"443\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://community-static.tradeup.com/news/41acba24cbc8a5959ece6e2d3eed987a","relate_stocks":{"NVO":"诺和诺德","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4007":"制药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","BK4599":"减肥药"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146985628","content_text":"8月6日，诺和诺德公布2025年第二季度财报：销售额为768.6亿丹麦克朗，同比增长13%，略低于市场预期的769.9亿丹麦克朗；净利润为265亿丹麦克朗，同比增长32%，低于预期的270.1亿丹麦克朗；息税前利润（EBIT）为334.5亿丹麦克朗，亦低于预期的344.5亿丹麦克朗。核心产品方面，减重药Wegovy销售额达195.3亿丹麦克朗，超出市场预期（192亿）；糖尿病药Ozempic销售额为318亿丹麦克朗，略低于预期的322.2亿。诺和诺德上半年净销售额为1549.44亿丹麦克朗，同比增长16%；净利润为555.37亿丹麦克朗，同比增长22%；稀释每股收益为12.49美元，同比增长23%。诺和诺德表示，目前预计全年自由现金流将达到350亿至450亿丹麦克朗。诺和诺德预计，未来几年资本支出占销售额的比例将维持在低双位数区间（即10%-15%左右）。诺和诺德仍预计按固定汇率计算，全年销售额增长8%至14%。财报发布后，诺和诺德夜盘涨超2%。","news_type":1,"symbols_score_info":{"NVO":1}},"isVote":1,"tweetType":1,"viewCount":6,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":31,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}